Test Bank For Clayton’s Basic Pharmacology for Nurses 19th Edition
m m m m m m m m m m
By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Com
m m m m m m m m m
plete
,Chapter m01:mDrug mDefinitions,mStandards,mandmInformationmSources mWillihnga
nz:mClayton’s mBasic mPharmacology mformNurses,m19thmEdition
MULTIPLEmCHOICE
1. Whichmnamemidentifiesmamdrugmlisted mbymthemUSmFood ma
nd mDrugmAdministrationm(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:mC
Themofficialmnamem ismthem namemundermwhichm amdrugmism listed
mbymthemFDA.mThembrand mname,mormtrademark, mismthemnamem
givenmtomamdrugmbymitsmmanufacturer.m Themnonproprietary,mo
rmgeneric,mname mis mprovided mbymthemUnited mStatesmAdopted m
NamesmCouncil.
DIF: CognitivemLevel:mKnowledge REF:m p.m9
OBJ:m1NAT:mNCLEXmClientmNeedsmCategory:mSafe,mEffectivemCa
remEnvironmentmTOP:m NursingmProcessmStep:mAssessment
CON:m
PatientmEducation
2. Whichmsourcemcontainsminformationmspecificmtomnutritionalmsupplements?
a. USPmDictionarymofmUSANm&mInternationalmDrugmNames
b. NaturalmMedicinesmComprehensivemDatabase
c. UnitedmStatesmPharmacopoeia/NationalmFormularym(USPmNF)
d. DrugmInteractionmFacts
ANS:mC
UnitedmStatesmPharmacopoeia/NationalmFormularymcontainsminformationmspecificmtomnutrition
almsupplements.mUSPmDictionarymofmUSANm&mInternationalmDrugmNamesmismamcompilationmof m
drugmnames,mpronunciationmguide,mand mpossiblemfuturemFDA mapproved mdrugs;mit mdoesmnot mincl
udemnutritionalmsupplements.mNaturalmMedicinesmComprehensivemDatabasemcontains
evidence-
based minformationmonmherbalmmedicinesmand mherbalmcombinationmproducts;mit mdoesmnot minclude
minformationmspecificmtomnutritionalmsupplements.mDrugmInteractionmFactsmcontainsmcomprehe
nsiveminformationmonmdrugminteractionmfacts;mit mdoesmnot mincludemnutritionalmsupplements.
DIF: CognitivemLevel:mKnowledge REF:m p.m4
OBJ:m3 mNAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmInt
egrity
TOP:m NursingmProcessmStep:mAssessment CON:m Nutrition m|mPatientmEducation
3. Whichmdrugmreferencemcontainsmdrugmmonographsmthat mdescribemallmdrugsminmamtherapeuticmclass?
a. DrugmFactsmandmComparisons
,Test mBank m FormClayton’sm BasicmPharmacology mformNursesm19thmEditi 3
on
b. DrugmInteractionmFacts
c. HandbookmonmInjectablemDrugs
d. Martindale—ThemCompletemDrugmReference
ANS:m A
DrugmFactsmandmComparisonsmcontainsmdrugmmonographsmthat mdescribemallmdrugsminma
mtherapeuticmclass.mMonographsmaremformatted masmtablesmtomallow mcomparison mof msimil
armproducts,mbrand mnames,mmanufacturers,mcost mindices,mand mavailablemdosagemformsm
Onlinemversionmismavailable.
DIF: CognitivemLevel:mKnowledge REF:m p.m4 mTablem1.2
OBJ:m m 3 NAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmIntegrity
TOP:m NursingmProcessmStep:mAssessment CON:m Safety m|mPatientmEducation m|mClinicalmJudgment
4. Whichmdrugmreferencemcontainsmmonographsmabout mvirtuallymeverymsingle-
entitymdrugmavailableminmthemUnited mStatesmand mdescribesmtherapeuticmusesmof mdrugs,mincludin
gmapproved mand munapproved muses?
a. Martindale:mThemCompletemDrugmReference
b. AHFSmDrugmInformation
c. DrugmReference
d. DrugmFactsmand mComparisons
ANS:m B
AHFSmDrugmInformationmcontainsmmonographsmabout mvirtuallymeverymsingle-
entitymdrugmavailableminmthemUnited mStatesmand mdescribesmtherapeuticmusesmof mdrugs,mincludingm
approved mand munapproved muses.
DIF: CognitivemLevel:mKnowledge REF:m p.m4 mTablem1.2
OBJ:m m 3 NAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmIntegrity
TOP:m NursingmProcessmStep:mPlanning CON:m Safety m|mPatientmEducation m|mClinicalmJudgment
5. Whichmonlinemdrugmreferencemmakesmavailablemtomhealthcaremprovidersmand mthempublicmamst
andard,mcomprehensive,mup-to-datemlookmupmand mdownloadablemresourcemabout mmedicines?
a. AmericanmDrugmIndex
b. AmericanmHospitalmFormulary
c. DailyMed
d. DrugmReference
ANS:mC
DailyMed mmakesmavailablemtomhealthcaremprovidersmand mthempublicmamstandard,mcomprehensiv
e,mup-to-
datemlookmupmand mdownloadablemresourcemabout mmedicines.mThemAmericanmDrugmIndexmismnot
mappropriatemformpatient muse.mThemAmericanmHospitalmFormularymismnot mappropriatemformpatie
nt muse.mThemdrugmreferencemismnot mappropriatemformpatient muse.
DIF: CognitivemLevel:mKnowledge REF:m p.m3 m|mp.m4
OBJ:m3 mNAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmInt
egrity
TOP:m NursingmProcessmStep:mImplementation
CON:m Safety m|mPatientmEducation m|mClinicalmJudgment
6. WhichmlegislationmauthorizesmthemFDA mtomdeterminemthemsafetymof mamdrugmbeforemitsmmarketing?
a. FederalmFood,mDrug,mand mCosmeticmAct m(1938)
b. DurhammHumphreymAmendment m(1952)
, Test mBank m FormClayton’sm BasicmPharmacology mformNursesm19thmEditi 4
on
c. Controlled mSubstancesmAct m(1970)
d. KefauvermHarrismDrugmAmendment m(1962)
ANS:m A
ThemFederalmFood,mDrug,mand mCosmeticmAct mof m1938mauthorized mthemFDA mtomdeterminemthems
afetymof mallmdrugsmbeforemmarketing.mLatermamendmentsmand mactsmhelped mtightenmFDA mcontrol
mand mensuremdrugmsafety.mThemDurhammHumphreymAmendment mdefinesmthemkindsmof mdrugsmth
at mcannot mbemused msafelymwithout mmedicalmsupervisionmand mrestrictsmtheirmsalemtomprescriptionm
bymamlicensed mpractitioner.mThemControlled mSubstancesmAct maddressesmonlymcontrolled msubstan
cesmand mtheirmcategorization.mThemKefauvermHarrismDrugmAmendment mensuresmdrugmefficacyma
nd mgreatermdrugmsafety.mDrugmmanufacturersmaremrequired mtomprovemtomthemFDA mthemeffectiven
essmof mtheirmproductsmbeforemmarketingmthem.
DIF: CognitivemLevel:mKnowledge REF:m p.m5 mTableml.3
OBJ:m 5
NAT:mNCLEXmClientmNeedsmCategory:mPhysiologicalmIntegrit
y mTOP:m NursingmProcessmStep:mAssessment
CON:m Safety m|mPatientmEducation m|mEvidence m|mHealth mCaremLaw
7. Whichmclassificationmdoesmmeperidinem(Demerol)mfallmunder?
a. I
b. II
c. III
d. IV
ANS:m B
Meperidinem(Demerol)mismamSchedulemII mdrug;mit mhasmamhighmpotentialmformabusemand mmaymlead
mtomseverempsychologicalmand mphysicalmdependence.mSchedulemI mdrugsmhavemhighmpotentialmform
abusemand mnomrecognized mmedicalmuse.mSchedulemIII mdrugsmhavemsomempotentialmformabuse.mU
semmaymlead mtomlowmtommoderatemphysicalmdependencemormhighmpsychologicalmdependence.mSc
hedulemIVmdrugsmhavemlow mpotentialmformabuse.mUsemmaymlead mtomlimited mphysicalmormpsychol
ogicalmdependence.
DIF: CognitivemLevel:mKnowledge REF:m p.m10
OBJ:m2 mNAT:m NCLEXmClientmNeedsmCategory:mSafe,mEffectivemC
aremEnvironment
TOP:m NursingmProcessmStep:mAssessment CON:m PatientmEducation m|mAddiction m|mPain
8. Whichmactionmwould mthemFDA mtakemtomexpeditemdrugmdevelopment mand mapprovalmformanmoutbre
akmof msmallpox?
a. List msmallpoxmasmamhealthmorphanmdisease.
b. Omit mthempreclinicalmresearchmphase.
c. Extend mthemclinicalmresearchmphase.
d. Fast mtrackmtheminvestigationalmdrug.
ANS:mD
OncemthemInvestigationalmNew mDrugmApplicationmhasmbeenmapproved,mthemdrugmcanmreceivemh
ighest mprioritymwithinmthemagency,mwhichmismcalled mfast mtracking.mAmsmallpoxmoutbreakmwould
mbecomemamprioritymconcernminmthemworld.mOrphanmdiseasesmaremnot mresearched minmamprioritym
manner.mPreclinicalmresearchmis mnot momitted.mExtendingmanymphasemof mthemresearchmwould mme
anmamlongermtimemtomdevelopmamvaccine.mThemFDA mmust mensuremthat mall mphases mof mthempreclinic
almand mclinicalmresearchmphasemhavembeen mcompleted minmamsafemmanner.
DIF: CognitivemLevel:mKnowledge REF:m m p.m7 OBJ:m 5
m m m m m m m m m m
By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Com
m m m m m m m m m
plete
,Chapter m01:mDrug mDefinitions,mStandards,mandmInformationmSources mWillihnga
nz:mClayton’s mBasic mPharmacology mformNurses,m19thmEdition
MULTIPLEmCHOICE
1. Whichmnamemidentifiesmamdrugmlisted mbymthemUSmFood ma
nd mDrugmAdministrationm(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:mC
Themofficialmnamem ismthem namemundermwhichm amdrugmism listed
mbymthemFDA.mThembrand mname,mormtrademark, mismthemnamem
givenmtomamdrugmbymitsmmanufacturer.m Themnonproprietary,mo
rmgeneric,mname mis mprovided mbymthemUnited mStatesmAdopted m
NamesmCouncil.
DIF: CognitivemLevel:mKnowledge REF:m p.m9
OBJ:m1NAT:mNCLEXmClientmNeedsmCategory:mSafe,mEffectivemCa
remEnvironmentmTOP:m NursingmProcessmStep:mAssessment
CON:m
PatientmEducation
2. Whichmsourcemcontainsminformationmspecificmtomnutritionalmsupplements?
a. USPmDictionarymofmUSANm&mInternationalmDrugmNames
b. NaturalmMedicinesmComprehensivemDatabase
c. UnitedmStatesmPharmacopoeia/NationalmFormularym(USPmNF)
d. DrugmInteractionmFacts
ANS:mC
UnitedmStatesmPharmacopoeia/NationalmFormularymcontainsminformationmspecificmtomnutrition
almsupplements.mUSPmDictionarymofmUSANm&mInternationalmDrugmNamesmismamcompilationmof m
drugmnames,mpronunciationmguide,mand mpossiblemfuturemFDA mapproved mdrugs;mit mdoesmnot mincl
udemnutritionalmsupplements.mNaturalmMedicinesmComprehensivemDatabasemcontains
evidence-
based minformationmonmherbalmmedicinesmand mherbalmcombinationmproducts;mit mdoesmnot minclude
minformationmspecificmtomnutritionalmsupplements.mDrugmInteractionmFactsmcontainsmcomprehe
nsiveminformationmonmdrugminteractionmfacts;mit mdoesmnot mincludemnutritionalmsupplements.
DIF: CognitivemLevel:mKnowledge REF:m p.m4
OBJ:m3 mNAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmInt
egrity
TOP:m NursingmProcessmStep:mAssessment CON:m Nutrition m|mPatientmEducation
3. Whichmdrugmreferencemcontainsmdrugmmonographsmthat mdescribemallmdrugsminmamtherapeuticmclass?
a. DrugmFactsmandmComparisons
,Test mBank m FormClayton’sm BasicmPharmacology mformNursesm19thmEditi 3
on
b. DrugmInteractionmFacts
c. HandbookmonmInjectablemDrugs
d. Martindale—ThemCompletemDrugmReference
ANS:m A
DrugmFactsmandmComparisonsmcontainsmdrugmmonographsmthat mdescribemallmdrugsminma
mtherapeuticmclass.mMonographsmaremformatted masmtablesmtomallow mcomparison mof msimil
armproducts,mbrand mnames,mmanufacturers,mcost mindices,mand mavailablemdosagemformsm
Onlinemversionmismavailable.
DIF: CognitivemLevel:mKnowledge REF:m p.m4 mTablem1.2
OBJ:m m 3 NAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmIntegrity
TOP:m NursingmProcessmStep:mAssessment CON:m Safety m|mPatientmEducation m|mClinicalmJudgment
4. Whichmdrugmreferencemcontainsmmonographsmabout mvirtuallymeverymsingle-
entitymdrugmavailableminmthemUnited mStatesmand mdescribesmtherapeuticmusesmof mdrugs,mincludin
gmapproved mand munapproved muses?
a. Martindale:mThemCompletemDrugmReference
b. AHFSmDrugmInformation
c. DrugmReference
d. DrugmFactsmand mComparisons
ANS:m B
AHFSmDrugmInformationmcontainsmmonographsmabout mvirtuallymeverymsingle-
entitymdrugmavailableminmthemUnited mStatesmand mdescribesmtherapeuticmusesmof mdrugs,mincludingm
approved mand munapproved muses.
DIF: CognitivemLevel:mKnowledge REF:m p.m4 mTablem1.2
OBJ:m m 3 NAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmIntegrity
TOP:m NursingmProcessmStep:mPlanning CON:m Safety m|mPatientmEducation m|mClinicalmJudgment
5. Whichmonlinemdrugmreferencemmakesmavailablemtomhealthcaremprovidersmand mthempublicmamst
andard,mcomprehensive,mup-to-datemlookmupmand mdownloadablemresourcemabout mmedicines?
a. AmericanmDrugmIndex
b. AmericanmHospitalmFormulary
c. DailyMed
d. DrugmReference
ANS:mC
DailyMed mmakesmavailablemtomhealthcaremprovidersmand mthempublicmamstandard,mcomprehensiv
e,mup-to-
datemlookmupmand mdownloadablemresourcemabout mmedicines.mThemAmericanmDrugmIndexmismnot
mappropriatemformpatient muse.mThemAmericanmHospitalmFormularymismnot mappropriatemformpatie
nt muse.mThemdrugmreferencemismnot mappropriatemformpatient muse.
DIF: CognitivemLevel:mKnowledge REF:m p.m3 m|mp.m4
OBJ:m3 mNAT:m NCLEXmClientmNeedsmCategory:mPhysiologicalmInt
egrity
TOP:m NursingmProcessmStep:mImplementation
CON:m Safety m|mPatientmEducation m|mClinicalmJudgment
6. WhichmlegislationmauthorizesmthemFDA mtomdeterminemthemsafetymof mamdrugmbeforemitsmmarketing?
a. FederalmFood,mDrug,mand mCosmeticmAct m(1938)
b. DurhammHumphreymAmendment m(1952)
, Test mBank m FormClayton’sm BasicmPharmacology mformNursesm19thmEditi 4
on
c. Controlled mSubstancesmAct m(1970)
d. KefauvermHarrismDrugmAmendment m(1962)
ANS:m A
ThemFederalmFood,mDrug,mand mCosmeticmAct mof m1938mauthorized mthemFDA mtomdeterminemthems
afetymof mallmdrugsmbeforemmarketing.mLatermamendmentsmand mactsmhelped mtightenmFDA mcontrol
mand mensuremdrugmsafety.mThemDurhammHumphreymAmendment mdefinesmthemkindsmof mdrugsmth
at mcannot mbemused msafelymwithout mmedicalmsupervisionmand mrestrictsmtheirmsalemtomprescriptionm
bymamlicensed mpractitioner.mThemControlled mSubstancesmAct maddressesmonlymcontrolled msubstan
cesmand mtheirmcategorization.mThemKefauvermHarrismDrugmAmendment mensuresmdrugmefficacyma
nd mgreatermdrugmsafety.mDrugmmanufacturersmaremrequired mtomprovemtomthemFDA mthemeffectiven
essmof mtheirmproductsmbeforemmarketingmthem.
DIF: CognitivemLevel:mKnowledge REF:m p.m5 mTableml.3
OBJ:m 5
NAT:mNCLEXmClientmNeedsmCategory:mPhysiologicalmIntegrit
y mTOP:m NursingmProcessmStep:mAssessment
CON:m Safety m|mPatientmEducation m|mEvidence m|mHealth mCaremLaw
7. Whichmclassificationmdoesmmeperidinem(Demerol)mfallmunder?
a. I
b. II
c. III
d. IV
ANS:m B
Meperidinem(Demerol)mismamSchedulemII mdrug;mit mhasmamhighmpotentialmformabusemand mmaymlead
mtomseverempsychologicalmand mphysicalmdependence.mSchedulemI mdrugsmhavemhighmpotentialmform
abusemand mnomrecognized mmedicalmuse.mSchedulemIII mdrugsmhavemsomempotentialmformabuse.mU
semmaymlead mtomlowmtommoderatemphysicalmdependencemormhighmpsychologicalmdependence.mSc
hedulemIVmdrugsmhavemlow mpotentialmformabuse.mUsemmaymlead mtomlimited mphysicalmormpsychol
ogicalmdependence.
DIF: CognitivemLevel:mKnowledge REF:m p.m10
OBJ:m2 mNAT:m NCLEXmClientmNeedsmCategory:mSafe,mEffectivemC
aremEnvironment
TOP:m NursingmProcessmStep:mAssessment CON:m PatientmEducation m|mAddiction m|mPain
8. Whichmactionmwould mthemFDA mtakemtomexpeditemdrugmdevelopment mand mapprovalmformanmoutbre
akmof msmallpox?
a. List msmallpoxmasmamhealthmorphanmdisease.
b. Omit mthempreclinicalmresearchmphase.
c. Extend mthemclinicalmresearchmphase.
d. Fast mtrackmtheminvestigationalmdrug.
ANS:mD
OncemthemInvestigationalmNew mDrugmApplicationmhasmbeenmapproved,mthemdrugmcanmreceivemh
ighest mprioritymwithinmthemagency,mwhichmismcalled mfast mtracking.mAmsmallpoxmoutbreakmwould
mbecomemamprioritymconcernminmthemworld.mOrphanmdiseasesmaremnot mresearched minmamprioritym
manner.mPreclinicalmresearchmis mnot momitted.mExtendingmanymphasemof mthemresearchmwould mme
anmamlongermtimemtomdevelopmamvaccine.mThemFDA mmust mensuremthat mall mphases mof mthempreclinic
almand mclinicalmresearchmphasemhavembeen mcompleted minmamsafemmanner.
DIF: CognitivemLevel:mKnowledge REF:m m p.m7 OBJ:m 5
